Verified factor-similar pair

AVSC vs FNDA

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
87
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • AVSC has the higher backtested relative Sharpe (1.329 vs 1.059).
  • AVSC is cheaper on dividend valuation (132 vs 148, where 100 is each fund's historical median).
  • AVSC has the stronger regression fit (adjusted R-squared 0.986 vs 0.977).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

AVSC

Avantis U.S Small Cap Equity ETF
SMB
Adj. R2
0.986
Rel. Sharpe
1.329
Mkt beta
0.97
AUM
US$2.5B
MER
0.25%
Valuation
132

FNDA

Schwab Fundamental U.S. Small Company ETF
SMB
Adj. R2
0.977
Rel. Sharpe
1.059
Mkt beta
1.02
AUM
US$9.8B
MER
0.25%
Valuation
148

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
AVSC
+1.10
|t|
+24.6
FNDA
+0.74
|t|
+24.7
diff +0.36
HML
AVSC
+0.23
|t|
+4.9
FNDA
+0.26
|t|
+9.0
diff -0.03
RMW
AVSC
+0.10
|t|
+2.3
FNDA
+0.15
|t|
+4.3
diff -0.05
CMA
AVSC
+0.05
|t|
+1.0
FNDA
+0.04
|t|
+1.1
diff +0.01
UMD
AVSC
+0.04
|t|
+1.4
FNDA
+0.00
|t|
+0.1
diff +0.04

Why This Pair Matches

Exposure level
85
Exposure shape
99
Mkt beta diff
0.04
Rel. Sharpe diff
0.270

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

AVSC fund page FNDA fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.